Drug intelligence / Profile preview

SuperHMO

Development stage: Unknown
Lead developer: Layer Origin
Modality: Small Molecules
Administration: Oral

Overview

SuperHMO is a prebiotic dietary supplement developed by Layer Origin, consisting of a specific blend of five human milk oligosaccharides (HMOs): 2'-fucosyllactose (2'FL), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 6'-sialyllactose (6'SL), and 3'-sialyllactose (3'SL). It is designed to support the adult gut microbiome by selectively promoting the growth of beneficial bacteria, such as *Bifidobacteria*, and enhancing the production of short-chain fatty acids (SCFAs). Clinical evaluation (NCT06570330) has focused on its impact on gut health measurements and microbiome composition in healthy adults, demonstrating its potential to modulate the gut environment through selective fermentation by probiotic species.

Brand names: SuperHMO
Other names: SuperHMO prebiotic formulation

Beyond the preview

Go deeper on SuperHMO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SuperHMO.

Explore the full profile